Roche's TIG­IT fall­out caus­es GSK and iTeos to re-think their own I/O can­di­date

Both Glax­o­SmithK­line and iTeos Ther­a­peu­tics are go­ing to take a hard look at their ex­per­i­men­tal TIG­IT-tar­get­ing im­munother­a­py in the wake of Roche’s fail ear­li­er this week.

EOS-448, an IgG1an­ti-TIG­IT mon­o­clon­al an­ti­body de­signed to en­gage the Fc gam­ma re­cep­tor (FcγR), is be­ing “reeval­u­at­ed” by the part­ners, iTeos re­vealed in its first quar­ter fi­nan­cial re­port Thurs­day. And there may even be fur­ther de­lays go­ing for­ward: Ac­cord­ing to an iTeos com­pa­ny spokesper­son in an email to End­points News, the three reg­is­tra­tion-di­rect­ed tri­als that were due to po­ten­tial­ly kick off around the end of the year now will have to wait un­til next year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER